INTERNATIONAL PATENT: JANSSEN PHARMACEUTICA NV FILES APPLICATION FOR "N-PHENYL-2-(4-OXO-QUINAZOLIN-3(4H)-YL)PROPANAMIDE DERIVATIVES AS TMEM175 MODULATORS FOR REDUCING ALPHA-SYNUCLEIN AGGREGATION FOR THE TREATMENT OF PARKINSON'S DISEASE"

GENEVA, May 18 -- JANSSEN PHARMACEUTICA NV (Turnhoutseweg 302340 Beerse) filed a patent application (PCT/EP2025/081942) for "N-PHENYL-2-(4-OXO-QUINAZOLIN-3(4H)-YL)PROPANAMIDE DERIVATIVES AS TMEM175 MODULATORS FOR REDUCING ALPHA-SYNUCLEIN AGGREGATION FOR THE TREATMENT OF PARKINSON'S DISEASE" on Nov 05, 2025. With publication no. WO/2026/099248, the details related to the patent application was published on May 15, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): OEHLRICH, Daniel (c/o: Janssen Pharmaceutica NVTurnhoutseweg 302340 Beerse), MAMMOLITI, Oscar (c/o: Janssen Pharmaceutica NVTurnhouts...